In the PACE trial, 93% of the pts had failed at least two tki's; 53% had failed three or more. In the Synribo trial, 47% of CP patients and had failed 3 tki's. It's pretty clear the ITT population in both trials were pts who had failed multiple tki's.
ps nice catch on the median duration...the response data was from April 2012.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.